HomeProductsBioactive CompoundsTransporters & Ion ChannelsSGLTIpragliflozin
Chemical structure of CAS 761423-87-4

Ipragliflozin

CAS No.761423-87-4
MDL No.MFCD19443744
MFC21H21FO5S
MW404.50
InChI KeyAHFWIQIYAXSLBA-RQXATKFSSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Ipragliflozin is a glycoside.

CAS No.761423-87-4
Product NameIpragliflozin

Biological Targets

SLC5A2

Associated Conditions

type 1 diabetes mellitus·type 2 diabetes mellitus·diabetes mellitus
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Pharmacological aspects of the safety of gliflozins.

Pharmacological research • Vol. 118 • 2017
PMID: 27389050DOI: 10.1016/j.phrs.2016.07.001

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.

Journal of diabetes investigation • Vol. 7, Issue 3 • 2016
PMID: 27330723PMC: PMC4847891DOI: 10.1111/jdi.12422

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

Bioorganic & medicinal chemistry • Vol. 20, Issue 10 • 2012
PMID: 22507206DOI: 10.1016/j.bmc.2012.03.051

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Naunyn-Schmiedeberg's archives of pharmacology • Vol. 385, Issue 4 • 2012
PMID: 22139434DOI: 10.1007/s00210-011-0713-z

Documentation

Similar Products